Neutrolis Inc
Toby Fox has diverse work experience in the fields of science, research, and entrepreneurship. Toby co-founded Neutrolis Inc in 2017 and served as the Chief Scientific Officer until July 2020, and later became the Chief Executive Officer. Prior to that, they worked at the Universitätsklinikum Hamburg Eppendorf as a Principal Investigator from 2013 to 2019. Toby also held the position of Senior Staff Scientist at Karolinska institutet from 2013 to 2017. Toby Fox's earlier roles include being an Instructor at Harvard Medical School from 2008 to 2013 and a Postdoctoral Fellow from 2008 to 2012. Toby began their professional journey as an Intern at Capgemini in 2007. Toby Fox completed their Ph.D. at the Max Planck Institute for Infection Biology, where they worked as a PHD Student from 2004 to 2007.
Toby Fox's education history reveals that they attended Humboldt-Universität zu Berlin from 2004 to 2007. During this time, they pursued a Doctor of Philosophy degree in Immunology.
This person is not in any teams
This person is not in any offices
Neutrolis Inc
Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases. Although NETs represent one of the most important immunology discoveries in the past 20 years, there is no therapyon the market that effectively targets and removes NETs. Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and supported by a seasoned biotech executive with a track record of successful M&A. The company’s pipeline includes NTR-441 and NTR-10, that effectively removes NETs and halt their pathologic effects on end-organs. Neutrolis has a strong patent portfolio for new molecular entity and method of use. The lead molecule, NTR-441, is slated to enter clinical trials in 2021.